05Jan 2023
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B‐type natriuretic peptide level: Insights from the GALACTIC‐HF trial

Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B‐type natriuretic peptide level: Insights from the GALACTIC‐HF trial

N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) is predictive of outcomes and treatment response in patients with heart failure and reduced ejection fraction (HFrEF). To examine the effect of the cardiac myosin activator omecamtiv mecarbil according to baseline NT‐proBNP level in the Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure trial (GALACTIC‐HF). In GALACTIC-HF, the benefit of omecamtiv mecarbil appeared to be larger in patients with higher baseline NT-proBNP levels, especially in patients without AF/AFL.

  • #cardiology

Like

Save

Share